Jw Life Science Corp (234080) — Cash Flow Quality Index
Jw Life Science Corp (234080) has a Cash Flow Quality Index of 2.12x as of March 2026. Operating cash flow of ₩14.17 Billion exceeds net income of ₩6.69 Billion, indicating high earnings quality where cash backs reported profits. Explore Jw Life Science Corp debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Jw Life Science Corp Cash Flow Quality Index (2015–2025)
Historical Cash Flow Quality Index for Jw Life Science Corp across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Jw Life Science Corp (234080) cash flow conversion.
Annual Cash Flow Quality Index for Jw Life Science Corp (2015–2025)
Year-by-year earnings quality comparison for Jw Life Science Corp.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.42x | ₩40.54 Billion | ₩28.61 Billion | ▲ +23.0% |
| 2024 | 1.15x | ₩50.69 Billion | ₩43.99 Billion | ▼ -13.7% |
| 2023 | 1.34x | ₩37.57 Billion | ₩28.14 Billion | ▲ +41.4% |
| 2022 | 0.94x | ₩14.13 Billion | ₩14.96 Billion | ▼ -59.6% |
| 2021 | 2.34x | ₩30.17 Billion | ₩12.91 Billion | ▲ +44.6% |
| 2020 | 1.62x | ₩46.75 Billion | ₩28.94 Billion | ▲ +48.8% |
| 2019 | 1.09x | ₩24.28 Billion | ₩22.35 Billion | ▼ -52.4% |
| 2018 | 2.28x | ₩36.13 Billion | ₩15.82 Billion | ▲ +73.8% |
| 2017 | 1.31x | ₩22.05 Billion | ₩16.78 Billion | ▲ +23.9% |
| 2016 | 1.06x | ₩16.08 Billion | ₩15.16 Billion | ▼ -47.3% |
| 2015 | 2.01x | ₩25.90 Billion | ₩12.86 Billion | — |